Advertisement
Genzyme
Subscribe to Genzyme

The Lead

Genzyme Collaborates on Gene Therapy for Rare Disease that Causes Childhood Blindness

September 24, 2014 8:32 am | News | Comments

Genzyme, a Sanofi company, today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness.

Genzyme Receives Label Expansion for Lumizyme® in the U.S. for the Treatment of Pompe Disease

August 4, 2014 8:40 am | News | Comments

Genzyme, a Sanofi company announced that the FDA approved a supplement to expand the indication...

Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center

April 30, 2014 11:40 am | News | Comments

Genzyme, a Sanofi company has announced the formation of a research collaboration with Cleveland...

Genzyme’s Lemtrada® Approved in Mexico for Treatment of Multiple Sclerosis

February 4, 2014 8:18 am | News | Comments

Genzyme has announced that Mexico’s national regulatory authority, COFEPRIS, has approved...

View Sample

FREE Email Newsletter

Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases

January 13, 2014 8:17 am | News | Comments

Genzyme, a Sanofi company , and Alnylam Pharmaceuticals, Inc. announced today that they have significantly expanded their strategic agreement to develop and commercialize treatments for rare genetic diseases. Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates.

Genzyme Multiple Sclerosis Drug Not Approved in US

January 2, 2014 8:08 am | News | Comments

The U.S. Food and Drug Administration has notified drug maker Genzyme that its treatment for multiple sclerosis is not ready for approval for the American market.              

Genzyme to Invest $80M in Framingham, Mass. Site to Expand Manufacturing Capacity for Fabrazyme®

October 15, 2013 8:27 am | News | Comments

Genzyme, a Sanofi company, is investing $80 million to build a new downstream processing facility for Fabrazyme® (agalsidase beta). The new plant, which will be located adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, Massachusetts, will significantly expand purification capacity to support anticipated growth in global demand over the coming years.

Advertisement

FDA Approves Two Drugs, Companion Diagnostic Test for Advanced Skin Cancer

May 29, 2013 3:30 pm | News | Comments

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

Genzyme’s AUBAGIO® Approved in Argentina for the Treatment of Relapsing MS

April 8, 2013 9:42 am | News | Comments

Genzyme, a Sanofi company, announced today Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved once-daily, oral AUBAGIO® 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

FDA Gives New Drug Application Approval to Isis

January 30, 2013 3:27 am | News | Comments

Drug developer Isis Pharmaceuticals Inc. and partner Genzyme announced Tuesday that the U.S. Food and Drug Administration has approved their new drug application for Kynamro, clearing the way for Isis' first drug to reach market.

Genzyme Receives European Label Expansion for Thyrogen

December 7, 2012 2:55 am | News | Comments

Genzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen®.

Isis Pharma Gets $1.1M Payment from Alnylam

October 24, 2012 4:13 am | News | Comments

NEW YORK (AP) — Isis Pharmaceuticals Inc. said Tuesday that it will get $1.1 million from Alnylam Pharmaceuticals Inc. as part of Alnylam's new collaboration with Genzyme.  

Advertisement

Isis Trading Halts as FDA Reviews Key Drug's Risks

October 19, 2012 3:57 am | by The Associated Press | News | Comments

Drug developer Isis Pharmaceuticals Inc. and partner Genzyme said Thursday a panel of advisers to the Food and Drug Administration had voted 9 to 6 to recommend approval of Kynamro, for treating patients genetically predisposed to have sky-high LDL, or bad cholesterol.  

FDA Approves Genzyme’s AUBAGIO®, a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis

September 13, 2012 4:09 am | News | Comments

Genzyme, a Sanofi company, announced today that the FDA has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

Impax Laboratories Announces Settlement of Litigation with Genzyme

September 4, 2012 4:04 am | News | Comments

Impax Laboratories, Inc. today announced that it has reached agreement with Genzyme, a Sanofi company, to settle pending U.S. litigation with regard to the production and sale of generic formulations of RENVELA® (sevelamer carbonate 800 mg tablet and oral suspension 2.4g and 0.8g) and RENAGEL® (sevelamer hydrochloride 400 mg and 800 mg tablets).

Genzyme and Isis Announce Filing of U.S. NDA for KYNAMRO

May 29, 2012 4:12 am | News | Comments

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced today that the FDA has accepted for filing the New Drug Application (NDA) for KYNAMRO™ (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The NDA filing with the FDA triggers a $25 million milestone payment to Isis from Genzyme.  

Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Plant

May 3, 2012 10:19 am | by Business Wire | News | Comments

Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced Thursday that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved a second suite for filling and finishing product at its Waterford, Ireland manufacturing plant.

Advertisement

Genzyme’s Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design

April 19, 2012 4:17 am | News | Comments

Genzyme, a Sanofi company, today announced that its Biologics Support Center in Framingham, Mass., received a Gold certification under the U.S. Green Building Council's LEED ® (Leadership in Energy and Environmental Design) Green Building Rating System™. This is the tenth Genzyme building to achieve a LEED rating for sustainable construction and design.  

Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant

March 1, 2012 3:42 am | News | Comments

Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme® (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts.

Genzyme Announces European Approval of Framingham Manufacturing Plant

January 18, 2012 3:04 am | News | Comments

Genzyme has announced that the EMA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme(R).

Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs

November 16, 2011 3:55 am | News | Comments

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

Genzyme Appoints Leaders for Multiple Sclerosis and Rare Disease Businesses

November 10, 2011 3:30 am | News | Comments

Genzyme announced today the appointment of William "Bill" Sibold as Head of Multiple Sclerosis and Rogerio Vivaldi as Head of Rare Diseases. Both will report to David Meeker, President and Chief Executive Officer of Genzyme, and will join the Genzyme Executive Team. The MS and Rare Disease businesses constitute Genzyme's core focus following its integration with Sanofi.

Sanofi Appoints New CEO of Genzyme

October 25, 2011 6:05 am | News | Comments

Sanofi announced Monday the appointment of current Genzyme COO David Meeker to the role of CEO of Genzyme effective November 1. Meeker will report to Sanofi CEO Christopher A. Viehbacher, who will retain the position of chairman of Genzyme.  

PTC Therapeutics and Genzyme Restructure Collaboration

September 2, 2011 4:24 am | News | Comments

PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration.

Aveo Pharma Elects Genzyme CEO Termeer to Board

April 12, 2011 4:41 am | News | Comments

CAMBRIDGE, Mass. (AP) — Aveo Pharmaceuticals Inc. said today it appointed Henri Termeer, the outgoing chairman, CEO and president of Genzyme Corp., to the Aveo board of directors.

Genzyme Board Recommends Shareholders Accept sanofi-aventis Revised Offer

March 7, 2011 3:46 am | News | Comments

Genzyme Corporation announced today that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share.

Genzyme Closes Pharma Intermediates Business Sale

March 1, 2011 9:27 am | News | Comments

CAMBRIDGE, Mass. (AP) —Genzyme Corp. said today that it completed the sale of its pharmaceutical intermediates business, finishing a plan announced last year to sell three businesses so it can focus on core growth areas.

Consent Decrees - Just the Cost of Doing Business?

February 28, 2011 3:31 am | by The QA Pharm | Blogs | Comments

The strategic reasons behind the acquisition in the works for Sanofi to purchase Genzyme are clear. It was a matter of fixing a sale price that reflected the true current and future value of Genzyme.

Genzyme Completes Sale of Diagnostics Business to Sekisui Chemical Co.

February 1, 2011 4:35 am | News | Comments

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading